Kalkine has a fully transformed New Avatar.

KALIN®

Kalkine Daily 26/03/2015 + Upcoming IPO's

Mar 26, 2015

In today’s daily we have covered stock research on Upcoming IPO's.








 

The S&P 500 was down by 29.21 points or 1.40% on Wednesday and closed at 2061.44 points.  U.S. stocks dropped on Wednesday as a slump in technology and biotech shares sent the Nasdaq to its biggest decline in almost a year, while the S&P 500 fell through key support levels. Technology stocks in the S&P 500 fell the most on Wednesday, down 2.4%.  European stocks fell. Germany’s DAX declined 1.2% and France’s CAC 40 lost 1.3%. The S&P 500 closed 1.5 per cent lower at 2,061.10 while the Dow Jones Industrial Average slipped 1.6 per cent to 17,718.94. The Nasdaq Composite closed 2.4 per cent lower to 4,876.52. The sell-off in US shares was accompanied by a 14 per cent jump in volatility, as measured by the CBOE's VIX volatility index, to 15.53. 
 
Kraft Foods Group Inc. and H.J. Heinz Co. agreed to merge. The combined company will be called The Kraft Heinz Co. and would be the world’s fifth-largest food-and-beverage company. Kraft shares surged 35%.  Lam ResearchAvago Technologies and Nvidiawere among the worst performing stocks on the S&P 500. Energy bucked the trend and was the only sector to close higher, following a rally in oil prices. Brent crude, the global oil marker, climbed 2 per cent to $56.25 a barrel, while West Texas Intermediate, the US benchmark, advanced 3 per cent to $48.99 a barrel.




Kraft Foods Daily Chart (Source - Thomson Reuters)
 

S&P ASX 200 was up by 4.20 points or 0.07% on Wednesday and closed at 5973.3 points. Among the big miners, BHP fell 0.3 per cent to $31.11 and Rio Tinto lost 0.9 per cent to $56.83. Commonwealth Bank of Australia added 0.8 per cent to $95.86, National Australia Bank put on 0.9 per cent to $39.30, Westpac lifted 0.8 per cent to $39.89 andANZ gained 0.8 per cent to $37.19, with the latter two closing at record highs. Woolworthsdropped 0.3 per cent to $28.96 while competitor Wesfarmers shed 0.3 per cent to $44.07.

Crop protection group Nufarm tumbled 2.5 per cent after reporting a 23 per cent jump in first-half profit to $23.2 million despite continuing dry conditions hurting its farmer customers in parts of Australia and the US. SPI futures are down 33 points. The Australian dollar is trading at US78.38¢, compared with Wednesday's local close of US78.78¢. Ore with 62 per cent iron content delivered to Qingdao, China, was down US5¢, or 0.09 per cent, to trade at $US55.81 a dry metric tonne. BC Iron, meanwhile, pushed ahead with its cost-cutting efforts after signing a new mining contract at its Nullagine joint venture in Western Australia. BC Iron was up 2.4 per cent to 42¢. Australia's largest soft-drink bottler, Coca-Cola Amatil, fell 0.2 per cent to $10.76.
 



Nufarm Daily Chart (Source – Thomson Reuters)

 
Top Performers on the ASX 200 were :-

 


 

Get up to 2 Years of free subscription by inviting your friends to KALKINE!

For every friend of yours who joins KALKINE, we'll give you 3 months of free subscription (up to a limit of 24 months free subscription). If you recommend 3 friends and they join within a month of you referring them, you get 1 year free subscription to KALKINE reports added to your account (up to a limit of 24 months free subscription). Simply reply to this email with their name, e-mail and phone number.
 



Upcoming IPO's Video


 

Snapshot of the upcoming IPO's

Skydive the Beach Group Limited is a skydiving company having about 11 existing drop zones across Australia. The Company also seems to acquire another five drop zones on Australia’s East Coast. Through the Initial Public Offer (IPO), the Company expects to raise about $20 million of capital (ASX proposed code: SKB). The Company lodged a Replacement Prospectus with the Australian Securities and Investments Commission replacing the original prospectus dated and lodged on 19 February 2015. The offer extends up to 80,000,000 fully paid shares for $0.25 per share with the ability to raise a further $5,000,000 in oversubscriptions. Normal trading of Shares on ASX is expected around 30 March 2015. The Company expects to use the offer proceeds for funding the proposed acquisition of Australia Skydive and to retire some debt among other requirements. A dividend with respect to FY15 ending 30 June 2015 of $0.01 per share is expected to be payable to shareholders in October 2015 subject to certain conditions.



Skydive the Beach Group Limited_Financials (Source – Company Reports)

ALT Resources Limited (ASX proposed code: ARS), known to be an Australian based mineral exploration entity, incorporated in April 2014 and set to acquire up to 70% interest in tenements held by GFM Exploration Pty Ltd, is looking forward to raise a capital for exploration of about $4 million. GFM is the registered holder of three tenements in the south-east Lachlan Orogen in New South Wales. The Company lodged its prospectus for inviting applications for shares on or around 5 February 2015. The IPO, led by Novus Capital, is supposed to have the listing dates later the present quarter or sometime early 2Q 2015. The Company has even extended the closing date of the offer to 15 May 2015. This IPO may open-up the opportunity in an early stage base and metal company for many investors. Operational drilling programs planned for the current year can be striking points. The Paupong Project, which is a new greenfields discovery by GFM exploration, illustrates a major gold bearing quartz-sulphide vein system extending over an area of 25 square km at the surface. This project is drill ready and is supported by the approval granted by the NSW Department Trade and Industry Resources and Energy for about 100 Reverse Circulation and Diamond Core holes. Another project, the Myalla Prospect (EL 8164), situated 30 km from the Paupong Project covering 54 square km has shown good prospects with gold bearing sulphide mineralization and the possibility of a near surface monzogranite in the south-west of the tenement.


Alt Resources Prospects (Source – Company Reports)

Proteomics International Laboratories Ltd provides solutions in the domain of biological research and drug discovery with simple diagnostic tests for common diseases. The Company is also engaged in discovering new therapeutic drugs. The Company recently announced for the finalization of an agreement with regards to a deal potentially worth $312m annually with New Summit Biopharma (Chinese bio-pharmaceutical company) to commercialise its diabetic kidney diagnostic in China. This is reported to be the first-ever proteomics derived In-Vitro Diagnostic for Chinese market. The Company aims to provide investors with pioneering exposure to the proteomics field through extensive research and development. The Company is known to be world’s first ISO proteomics laboratory accreditation for its Perth facility in 2009. Through the IPO, the Company aimed to float 30m shares on offer at a listing price of $0.20 and market capitalization is expected to be of the order of $13.1 million (ASX proposed code: PIQ). The shares will commence trading on the ASX in March/April 2015. The benefits from the listing will be directed towards R&D activities supplemented by cashflow from contract research operations. There is a good indication by the Company that the major growth opportunity for new investors circumscribes around Proteomics’ intellectual property portfolio with its key asset entailing a patent-pending diagnostics test for diabetic kidney disease expected to be commercialised through a licensing agreement within 12 months. The recent launch of the unique test called “2tag” (patent-protected) for oxidative stress is also an important landmark development.



Another such entity is Genetic Signatures Limited, the developer of 3base™ technology, which has also been known for the development and commercialization of EasyScreen™ Real-Time PCR based kits for routine detection of infectious diseases. This area proffers immense potential with regards to the molecular tools required by hospitals and pathology laboratories for screening a wide array of infectious pathogens in a rapid and high-throughput environment.


Genetic Signatures Financials (Source – Company Reports)


The Company has highlighted that its customer base primarily constitutes large hospital and pathology laboratories in Australia, however, the target base includes markets in the US and the EU as the Company’s products have been developed to meet existing and planned future requirements in said markets as well. Through the IPO, the Company expected to raise capital of about $15 million. The Company has recently announced about successful closing of the IPO at the maximum raising of 7.5 million. It has further informed that it expects the listing of shares, which are to be issued at $0.40 per share, on the ASX on 31 March 2015 (ASX proposed code: GSS).


 


Level 13  167 Macquarie Street
Sydney NSW 2000 Australia
E-Mail - [email protected]
Phone - 02 8667 3147


        
Note - You can also view this daily in the special reports section.

 


Disclaimer
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people.
Kalkine.com.au and associated pages are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376).
The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation.
Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product.
The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide.